Claudio Jeldres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9166524/publications.pdf

Version: 2024-02-01

26610 51562 8,742 160 56 86 citations g-index h-index papers 163 163 163 7173 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. European Urology, 2012, 61, 679-685.	0.9	345
2	Radical versus partial nephrectomy. Cancer, 2009, 115, 1465-1471.	2.0	285
3	Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2008, 53, 917-930.	0.9	226
4	Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. Cancer Epidemiology, 2013, 37, 219-225.	0.8	222
5	A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate Cancer. Journal of Clinical Oncology, 2007, 25, 3576-3581.	0.8	205
6	The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. European Journal of Cancer, 2010, 46, 713-719.	1.3	191
7	Câ€reactive protein is an informative predictor of renal cell carcinomaâ€specific mortality. Cancer, 2007, 110, 1241-1247.	2.0	165
8	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. European Urology, 2010, 57, 300-309.	0.9	159
9	A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988–2006. European Urology, 2011, 59, 88-95.	0.9	159
10	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. European Urology, 2010, 57, 1072-1079.	0.9	155
11	Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: A population-based study of 2299 patients. European Journal of Cancer, 2009, 45, 3291-3297.	1.3	151
12	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. Journal of Urology, 2010, 183, 68-75.	0.2	146
13	A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma. Urology, 2010, 75, 118-124.	0.5	144
14	A Population Based Assessment of Perioperative Mortality After Cystectomy for Bladder Cancer. Journal of Urology, 2009, 182, 70-77.	0.2	131
15	Clinicians are poor raters of lifeâ€expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU International, 2007, 100, 1254-1258.	1.3	129
16	Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. European Urology, 2008, 53, 845-848.	0.9	123
17	A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma. European Urology, 2009, 55, 287-295.	0.9	121
18	Pathological results and rates of treatment failure in highâ€risk prostate cancer patients after radical prostatectomy. BJU International, 2011, 107, 765-770.	1.3	120

#	Article	IF	CITATIONS
19	A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a populationâ€based study. BJU International, 2009, 103, 1496-1500.	1.3	118
20	Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men. European Urology, 2008, 54, 1306-1313.	0.9	114
21	Can nomograms be superior to other prediction tools?. BJU International, 2009, 103, 492-497.	1.3	108
22	Location of the Primary Tumor is Not an Independent Predictor of Cancer Specific Mortality in Patients With Upper Urinary Tract Urothelial Carcinoma. Journal of Urology, 2009, 182, 2177-2181.	0.2	106
23	Gender-related Differences in Patients With Stage I to III Upper Tract Urothelial Carcinoma: Results From the Surveillance, Epidemiology, and End Results Database. Urology, 2010, 75, 321-327.	0.5	106
24	Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer. Urology, 2009, 73, 1087-1091.	0.5	102
25	Segmental Ureterectomy Can Safely be Performed in Patients With Transitional Cell Carcinoma of the Ureter. Journal of Urology, 2010, 183, 1324-1329.	0.2	102
26	Nephron-sparing Surgery Is Equally Effective to Radical Nephrectomy for T1BNOMO Renal Cell Carcinoma: A Population-based Assessment. Urology, 2010, 75, 271-275.	0.5	98
27	Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. Journal of Urology, 2009, 182, 78-84.	0.2	93
28	The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study on 17,845 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 76, 342-348.	0.4	93
29	A Population-based Assessment of Perioperative Mortality After Nephroureterectomy for Upper-tract Urothelial Carcinoma. Urology, 2010, 75, 315-320.	0.5	93
30	Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular Markers. Journal of Urology, 2010, 183, 1744-1750.	0.2	91
31	Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. Annals of Surgical Oncology, 2012, 19, 2380-2387.	0.7	91
32	A populationâ€based competingâ€risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011, 117, 103-109.	2.0	89
33	Partial Versus Radical Nephrectomy in Patients With Adverse Clinical or Pathologic Characteristics. Urology, 2009, 73, 1300-1305.	0.5	87
34	Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A populationâ€based analysis. International Journal of Urology, 2012, 19, 836-844.	0.5	85
35	Should Bladder Cuff Excision Remain the Standard of Care at Nephroureterectomy in Patients with Urothelial Carcinoma of the Renal Pelvis? A Population-based Study. European Urology, 2010, 57, 956-962.	0.9	84
36	Decreasing Rate and Extent of Lymph Node Staging in Patients Undergoing Radical Prostatectomy May Undermine the Rate of Diagnosis of Lymph Node Metastases in Prostate Cancer. European Urology, 2010, 58, 882-892.	0.9	84

#	Article	IF	Citations
37	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 536-543.	1.3	77
38	Partial Cystectomy Does Not Undermine Cancer Control in Appropriately Selected Patients With Urothelial Carcinoma of the Bladder: A Population-based Matched Analysist. Urology, 2009, 74, 858-864.	0.5	77
39	Stageâ€specific effect of nodal metastases on survival in patients with nonâ€metastatic renal cell carcinoma. BJU International, 2009, 103, 33-37.	1.3	75
40	Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. Cancer, 2010, 116, 3774-3784.	2.0	73
41	Impact of chronic prostatitisâ€like symptoms on the quality of life in a large group of men. BJU International, 2007, 100, 1307-1311.	1.3	70
42	Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. Clinical Cancer Research, 2009, 15, 7012-7019.	3.2	69
43	p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU International, 2010, 105, 489-495.	1.3	69
44	Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort. European Urology, 2011, 60, 920-930.	0.9	69
45	Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma. Urology, 2009, 73, 342-346.	0.5	67
46	Tumor Size is a Determinant of the Rate of Stage T1 Renal Cell Cancer Synchronous Metastasis. Journal of Urology, 2009, 182, 1287-1293.	0.2	67
47	Prospective randomized trial of barbed polyglyconate suture to facilitate vesicoâ€urethral anastomosis during robotâ€assisted radical prostatectomy: time reduction and cost benefit. BJU International, 2012, 109, 1526-1532.	1.3	65
48	Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU International, 2012, 109, 1147-1154.	1.3	64
49	A Proposal for Reclassification of the Fuhrman Grading System in Patients with Clear Cell Renal Cell Carcinoma. European Urology, 2009, 56, 775-781.	0.9	62
50	Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma. Cancer, 2009, 115, 5680-5687.	2.0	61
51	A Population-based Comparison of Cancer-control Rates Between Radical and Partial Nephrectomy for T1A Renal Cell Carcinoma. Urology, 2010, 76, 883-888.	0.5	61
52	Adenocarcinoma Versus Urothelial Carcinoma of the Urinary Bladder: Comparison Between Pathologic Stage at Radical Cystectomy and Cancer-specific Mortality. Urology, 2010, 75, 376-381.	0.5	61
53	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. European Urology, 2013, 64, 837-845.	0.9	61
54	Thirty-Day Mortality After Nephrectomy: Clinical Implications for Informed Consent. European Urology, 2009, 56, 998-1005.	0.9	60

#	Article	IF	Citations
55	How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU International, 2011, 107, 1095-1101.	1.3	58
56	Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. Journal of Urology, 2012, 187, 405-410.	0.2	58
57	Prognostic Value of Extranodal Extension and Other Lymph Node Parameters in Patients With Upper Tract Urothelial Carcinoma. Journal of Urology, 2012, 187, 845-851.	0.2	57
58	p53 Predictive Value for pT1-2 NO Disease at Radical Cystectomy. Journal of Urology, 2009, 182, 907-913.	0.2	54
59	Conditional Survival Predictions After Nephrectomy for Renal Cell Carcinoma. Journal of Urology, 2009, 182, 2607-2612.	0.2	52
60	The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. Cancer Causes and Control, 2011, 22, 1085-1095.	0.8	51
61	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. European Journal of Cancer, 2012, 48, 1503-1511.	1.3	50
62	Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. International Journal of Urology, 2012, 19, 645-651.	0.5	50
63	Can Renal Mass Biopsy Assessment of Tumor Grade be Safely Substituted for by a Predictive Model?. Journal of Urology, 2009, 182, 2585-2589.	0.2	48
64	A comparative populationâ€based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. BJU International, 2010, 105, 359-364.	1.3	48
65	Is robotic surgery cost-effective. Current Opinion in Urology, 2012, 22, 61-65.	0.9	48
66	Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. Urology, 2009, 74, 373-377.	0.5	47
67	External Validation of the Updated Partin Tables in a Cohort of French and Italian Men. International Journal of Radiation Oncology Biology Physics, 2009, 73, 347-352.	0.4	46
68	Mortality at 120 days after prostatic biopsy: A populationâ€based study of 22,175 men. International Journal of Cancer, 2008, 123, 647-652.	2.3	44
69	Baseline renal function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy. BJU International, 2009, 103, 1632-1635.	1.3	44
70	Survival after radical cystectomy of nonâ€bilharzial squamous cell carcinoma vs urothelial carcinoma: a competingâ€risks analysis. BJU International, 2012, 109, 564-569.	1.3	44
71	Cytoreductive Partial Nephrectomy Does Not Undermine Cancer Control in Metastatic Renal Cell Carcinoma: A Population-Based Study. Urology, 2008, 72, 1090-1095.	0.5	43
72	A Stage-for-Stage and Grade-for-Grade Analysis of Cancer-Specific Mortality Rates in Renal Cell Carcinoma According to Age: A Competing-Risks Regression Analysis. European Urology, 2011, 60, 1152-1159.	0.9	43

#	Article	IF	CITATIONS
73	The Effect of Comorbidity and Socioeconomic Status on Sexual and Urinary Function and on General Health-Related Quality of Life in Men Treated with Radical Prostatectomy for Localized Prostate Cancer. Journal of Sexual Medicine, 2008, 5, 919-927.	0.3	41
74	Preâ€treatment biomarker levels improve the accuracy of postâ€prostatectomy nomogram for prediction of biochemical recurrence. Prostate, 2009, 69, 886-894.	1.2	40
75	Survival Benefit of Radical Prostatectomy in Patients with Localized Prostate Cancer: Estimations of the Number Needed to Treat According to Tumor and Patient Characteristics. Journal of Urology, 2012, 188, 73-83.	0.2	40
76	Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy. Canadian Urological Association Journal, 2013, 2, 610.	0.3	40
77	Prediction of delayed graft function after renal transplantation. Canadian Urological Association Journal, 2013, 3, 377.	0.3	39
78	Clinicians are Most Familiar with Nomograms and Rate their Clinical Usefulness Highest, Look-up Tables are Second Best. European Urology, 2008, 54, 958-959.	0.9	37
79	A populationâ€based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU International, 2009, 103, 899-904.	1.3	37
80	External Validation of the Updated Partin Tables in a Cohort of North American Men. Journal of Urology, 2008, 180, 898-903.	0.2	36
81	Radical cystectomy for patients with pT4 urothelial carcinoma in a large populationâ€based study. BJU International, 2011, 107, 905-911.	1.3	36
82	Development and Validation of a Reference Table for Prediction of Postoperative Mortality Rate in Patients Treated with Radical Cystectomy: A Population-based Study. Annals of Surgical Oncology, 2012, 19, 309-317.	0.7	36
83	A Simple and Accurate Model for Prediction of Cancer-Specific Mortality in Patients Treated with Surgery for Primary Penile Squamous Cell Carcinoma. Clinical Cancer Research, 2009, 15, 1013-1018.	3.2	34
84	A Contemporary Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma. Annals of Surgical Oncology, 2011, 18, 439-446.	0.7	34
85	Radical Prostatectomy at Academic Versus Nonacademic Institutions: A Population Based Analysis. Journal of Urology, 2011, 186, 1849-1854.	0.2	33
86	Poor Overall Survival in Septa- and Octogenarian Patients after Radical Prostatectomy and Radiotherapy for Prostate Cancer: A Population-Based Study of 6183 Men. European Urology, 2008, 54, 107-117.	0.9	32
87	The effect of surgical volume, age and comorbidities on 30â€day mortality after radical prostatectomy: a populationâ€based analysis of 9208 consecutive cases. BJU International, 2008, 101, 826-832.	1.3	30
88	Effect of Body Mass Index on Histopathologic Parameters: Results of Large European Contemporary Consecutive Open Radical Prostatectomy Series. Urology, 2009, 73, 615-619.	0.5	30
89	Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. European Journal of Cancer, 2007, 43, 1180-1187.	1.3	29
90	Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma. BJU International, 2008, 102, 1610-1614.	1.3	29

#	Article	IF	Citations
91	Tumor Grade Improves the Prognostic Ability of American Joint Committee on Cancer Stage in Patients With Penile Carcinoma. Journal of Urology, 2011, 185, 501-507.	0.2	29
92	Early Postoperative Plasma Transforming Growth Factor- \hat{l}^21 is a Strong Predictor of Biochemical Progression After Radical Prostatectomy. Journal of Urology, 2008, 179, 1593-1597.	0.2	28
93	Competing-Risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 95-103.	0.4	28
94	Nodeâ€positive renal cell carcinoma in the absence of distant metastases: predictors of cancerâ€specific mortality in a populationâ€based cohort. BJU International, 2012, 110, E21-7.	1.3	28
95	Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. BJU International, 2010, 105, 799-804.	1.3	27
96	Comparative Study of Inguinal Hernia Repair After Radical Prostatectomy, Prostate Biopsy, Transurethral Resection of the Prostate or Pelvic Lymph Node Dissection. Journal of Urology, 2010, 183, 970-976.	0.2	27
97	Race affects access to nephrectomy but not survival in renal cell carcinoma. BJU International, 2009, 103, 889-893.	1.3	26
98	Oncological and Functional Outcomes After Robot-assisted Radical Cystectomy: Critical Review of Current Status. Urology, 2011, 78, 977-984.	0.5	26
99	Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU International, 2007, 101, 071003001542001-???.	1.3	25
100	Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU International, 2008, 102, 33-38.	1.3	25
101	Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy. European Urology, 2009, 55, 617-628.	0.9	25
102	A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States. Urology, 2009, 74, 837-841.	0.5	25
103	Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. Cancer, 2012, 118, 1894-1900.	2.0	25
104	Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillance—How Many Cores are Enough?. Journal of Urology, 2015, 194, 674-679.	0.2	25
105	Unilateral Prostate Cancer Cannot be Accurately Predicted in Low-Risk Patients. International Journal of Radiation Oncology Biology Physics, 2010, 77, 784-787.	0.4	24
106	Impact of Caseload on Total Hospital Charges: A Direct Comparison Between Minimally Invasive and Open Radical Prostatectomy—A Population Based Study. Journal of Urology, 2011, 185, 855-861.	0.2	24
107	Risk factors for biochemical recurrence following radical perineal prostatectomy in a large contemporary series: A detailed assessment of margin extent and location. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1470-1476.	0.8	24
108	Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy. European Urology, 2007, 51, 949-955.	0.9	23

#	Article	IF	Citations
109	Baseline Prevalence of Erectile Dysfunction in a Prostate Cancer Screening Population. Journal of Sexual Medicine, 2008, 5, 428-435.	0.3	23
110	Laparoscopic Partial Nephrectomy: Predictors of Prolonged Warm Ischemia. Journal of Urology, 2009, 182, 860-865.	0.2	23
111	Predicting life expectancy in prostate cancer patients. Current Opinion in Supportive and Palliative Care, 2009, 3, 166-169.	0.5	23
112	Discharge patterns after radical prostatectomy in the United States of America. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1022-1032.	0.8	22
113	Development and External Validation of a Highly Accurate Nomogram for the Prediction of Perioperative Mortality After Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Journal of Urology, 2009, 182, 626-632.	0.2	21
114	Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU International, 2007, 100, 37-41.	1.3	19
115	External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU International, 2009, 104, 1661-1667.	1.3	19
116	The presence of prostate cancer on saturation biopsy can be accurately predicted. BJU International, 2010, 105, 636-641.	1.3	19
117	Higher perioperative morbidity and inâ€hospital mortality in patients with endâ€stage renal disease undergoing nephrectomy for nonâ€metastatic kidney cancer: a populationâ€based analysis. BJU International, 2012, 110, E183-90.	1.3	19
118	The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. International Journal of Urology, 2009, 16, 526-529.	0.5	18
119	Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU International, 2009, 104, 795-799.	1.3	18
120	Blood Transfusions in Radical Prostatectomy: A Contemporary Population-based Analysis. Urology, 2012, 79, 332-338.	0.5	18
121	Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy. Annals of Surgical Oncology, 2013, 20, 2096-2102.	0.7	18
122	High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. BJU International, 2008, 102, 463-467.	1.3	17
123	High Provider Volume is Associated with Lower Rate of Secondary Therapies after Definitive Radiotherapy for Localized Prostate Cancer. European Urology, 2008, 54, 97-106.	0.9	17
124	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. Cancer, 2012, 118, 4991-4998.	2.0	17
125	Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Canadian Urological Association Journal, 2009, 3, 13-21.	0.3	17
126	Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. BJU International, 2007, 99, 1404-1408.	1.3	16

#	Article	IF	CITATIONS
127	Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. European Urology, 2007, 52, 1374-1380.	0.9	16
128	Comparative Study of Inguinal Hernia Repair Rates After Radical Prostatectomy or External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1307-1313.	0.4	16
129	The Importance of Pelvic Lymph Node Dissection in the Elderly Population: Implications for Interpreting the 2010 National Comprehensive Cancer Network Practice Guidelines for Bladder Cancer Treatment. Journal of Urology, 2011, 185, 2078-2084.	0.2	16
130	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. Canadian Urological Association Journal, 2012, 6, 245-250.	0.3	16
131	Multi-Institutional External Validation of Seminal Vesicle Invasion Nomograms: Head-to-Head Comparison of Gallina Nomogram Versus 2007 Partin Tables. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1461-1467.	0.4	15
132	Does Histologic Subtype Affect Oncologic Outcomes After Nephron-sparing Surgery?. Urology, 2009, 74, 842-845.	0.5	15
133	Medical management of benign prostatic hyperplasia: Results from a population-based study. Canadian Urological Association Journal, 2016, 10, 55.	0.3	15
134	ORIGINAL RESEARCHâ€"MEN'S SEXUAL HEALTH: The Effect of Comorbidities and Socioeconomic Status on Sexual and Urinary Function in Men Undergoing Prostate Cancer Screening. Journal of Sexual Medicine, 2008, 5, 668-676.	0.3	14
135	Assessment of Biochemical Recurrence Rate in Patients With Pathologically Confirmed Insignificant Prostate Cancer. Urology, 2008, 72, 1208-1211.	0.5	13
136	A nomogram predicting metastatic progression after radical prostatectomy. International Journal of Urology, 2008, 15, 889-894.	0.5	12
137	Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort. Urology, 2009, 73, 1323-1327.	0.5	12
138	Surgical Caseload is an Important Determinant of Continent Urinary Diversion Rate at Radical Cystectomy: A Population-Based Study. Annals of Surgical Oncology, 2011, 18, 2680-2687.	0.7	11
139	The effect of insurance status on outcomes after partial nephrectomy. International Urology and Nephrology, 2012, 44, 343-351.	0.6	11
140	Body Mass Index and its Association with Genitourinary Disorders in Men Undergoing Prostate Cancer Screening. Journal of Sexual Medicine, 2008, 5, 2141-2151.	0.3	10
141	Training and outcome monitoring in robotic urologic surgery. Nature Reviews Urology, 2012, 9, 17-22.	1.9	10
142	Reply to Michael Staehler's Letter to the Editor re: Pierre I Karakiewicz, Nazareno Suardi, Claudio Jeldres, et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. Eur Urol 2008;53:845-848. European Urology, 2008, 54, 951-953.	0.9	9
143	Effect of body mass index on prostateâ€specific antigen and percentage free prostateâ€specific antigen: Results from a prostate cancer screening cohort of 1490 men. International Journal of Urology, 2009, 16, 91-95.	0.5	8
144	United States trends in patterns of care in clinical stage I testicular cancer: Results from the National Cancer Database (1998-2011) Journal of Clinical Oncology, 2014, 32, 369-369.	0.8	8

#	Article	IF	CITATIONS
145	Management of upper urinary tract urothelial carcinoma. Expert Review of Anticancer Therapy, 2010, 10, 1955-1965.	1.1	7
146	Does partial nephrectomy at an academic institution result in better outcomes?. World Journal of Urology, 2012, 30, 505-510.	1.2	7
147	The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. International Urology and Nephrology, 2012, 44, 799-806.	0.6	7
148	Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer. BJU International, 2010, 105, 818-823.	1.3	6
149	Life expectancy estimation in prostate cancer patients. Canadian Urological Association Journal, 2012, 6, 374-375.	0.3	6
150	Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011) Journal of Clinical Oncology, 2014, 32, 4519-4519.	0.8	5
151	Pazopanib trial data cannot support first-line use. Nature Reviews Urology, 2010, 7, 307-308.	1.9	4
152	Discharge Patterns After Radical Cystectomy: Contemporary Trends in the United States. Journal of Urology, 2012, 187, 1206-1209.	0.2	4
153	Thirty-Day Mortality After Transurethral Resection of the Prostate in Patients Treated with Androgen Deprivation Therapy. Journal of Endourology, 2009, 23, 1347-1352.	1.1	3
154	Suspected Clinical T3 Prostate Cancer Is Associated with a High Rate of Negative Extended Biopsies: Clinical Implications. European Urology, 2009, 55, 253-254.	0.9	3
155	Association of SPARC expression with metastatic progression and prostate cancer-specific mortality after radical prostatectomy Journal of Clinical Oncology, 2013, 31, 5071-5071.	0.8	2
156	Reply to Fabio Campodonico, Giacomo Capponi and Massimo Maffezzini's Letter to the Editor re: Vincent Cloutier, Umberto Capitanio, Laurent Zini, et al. Thirty-Day Mortality after Nephrectomy: Clinical Implications for Informed Consent. Eur Urol 2009;56:998–1005. European Urology, 2009, 56, e47.	0.9	0
157	Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. Open Access Journal of Urology, 2011, 3, 43.	0.3	0
158	Life expectancy estimation in prostate cancer patients. Canadian Urological Association Journal, 2012, 6, .	0.3	0
159	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma Journal of Clinical Oncology, 2012, 30, 281-281.	0.8	0
160	Influence of social demographics and African-American race on outcomes in testicular cancer: Analysis of 75,902 patients in the National Cancer database Journal of Clinical Oncology, 2014, 32, 391-391.	0.8	0